Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Advancing In Vivo Insights: Mastering Bioluminescent Imaging for Dynamic Biological Studies

In this webinar, you will learn how:

  • Essential factors like desired sensitivity and throughput will influence your BLI design
  • To evaluate equipment to ensure low light detection and quantification
  • NanoLuc® Luciferase broadens the scope of bioluminescent reporter applications for novel in vivo BLI models, including multiplexed reporter imaging experiment

Summary

Are you developing an in vivo small animal bioluminescent imaging (BLI) model? Are you interested in the latest tools and techniques that expand the capabilities of traditional BLI? In vivo bioluminescent imaging is a non-invasive method to monitor biological events in living animals, enabling the study of dynamic processes in real-time within a complex biological system. Before investing time and resources in developing an in vivo BLI model, it is important to ensure you have optimized the design to meet your experimental goals. Join our featured experts from Promega and Spectral Instruments Imaging where they will walk through the three basic elements of any in vivo BLI experiment: the bioluminescent reporter protein, the reporter substrate, and the instrument you will use to measure the bioluminescent signal.  They will also discuss key considerations for each of these elements and provide application examples, such as in vivo CAR-T cell tracking, that demonstrate how different experimental goals can influence your model design. 

Speakers

2579-thomas-kirkland-125

Thomas Kirkland, PhD
Senior Scientific Investigator
Promega

Thomas Kirkland is a senior scientific investigator within the Advanced Technology Group, Promega’s early research division.  Tom received his Ph.D. in Organic Chemistry at the California Institute of Technology and did a postdoctoral fellowship at the University of Texas at Austin.  At Promega he is responsible for creating partnerships with academic and governmental researchers with the goal of co-inventing broadly useful tools for life science research.  His research is broadly based on using chemistry to detect the states and interactions of biomolecules in simple and complex environments.  In one of his recent efforts he has driven development of bioluminescent substrates for the small bright luciferase NanoLuc that work well in vivo in collaboration with the lab of Michael Lin at Stanford University.
andrew-van-praagh-image-125

Andrew Van Praagh, PhD
Lead Applications Scientist
Spectral Instruments Imaging

Andrew Van Praagh is a lead applications scientist within the global sales and marketing team of Spectral Instruments Imaging (SII).  Andrew received his Ph.D. in Microbiology at the University of Massachusetts, Amherst, and then joined the pharmaceutical industry sector as a scientist in the Pharmacology Department at Cubist Pharmaceuticals, in Lexington, MA.  At SII, Andrew is responsible for leading a wide range of investigator support services and collaborations that include: (i) technical seminars (ii) the development of support materials and (iii) live demonstrations and advanced training sessions with SII deeply-cooled, CCD optical imaging systems. In a recent effort, Andrew and SII colleagues presented data at WMIC (poster session, 2023) illustrating how advances in SII Aura software platform have enabled optical imaging to be performed with greater ease, speed and sensitivity, while maintaining data quantitative accuracy.